A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of KRP-104 in Patients With Type 2 Diabetes Inadequately Controlled on Metformin Alone
Primary Purpose
Type 2 Diabetes
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
KRP-104 QD Drug: Placebo Drug: Metformin
Placebo Drug: Metformin
KRP-104 BID Drug: Placebo Drug: Metformin
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes
Eligibility Criteria
Inclusion Criteria:
- Age 18 to 70 years, inclusive;
- Males and females of non-childbearing potential;
- Diagnosis of type 2 diabetes mellitus according; and
- On a stable dose of metformin monotherapy at randomization (can be on other oral therapies or naive at study entry
Exclusion Criteria:
- History of type 1 diabetes mellitus or history of diabetic ketoacidosis or persistent hypoglycemia;
- History or presence of alcoholism or drug abuse
- Typical consumption of ≥10 drinks of alcohol weekly;
Presence of any of the following conditions:
- Significant renal impairment (glomerular filtration rate <60 mL/min [to be calculated by the central laboratory]);
- Diabetic retinopathy;
- Diabetic gastroparesis;
- Active liver disease (other than asymptomatic nonalcoholic fatty liver disease), cirrhosis, or symptomatic gallbladder disease;
- Uncontrolled high blood pressure;
- History or evidence of cardiovascular or pulmonary disease
- Must meet other laboratory and Medical History clinical criteria. Please contact recruitment center for referrals
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Placebo Comparator
Arm Label
KRP-104 120 mg QD
KRP-104 60 mg BID
Placebo
Arm Description
Outcomes
Primary Outcome Measures
The primary objective of this trial is to demonstrate the hemoglobin A1c (HbA1c)-lowering effects of KRP-104 in patients with type 2 diabetes inadequately controlled on metformin alone.
Secondary Outcome Measures
To assess the fasting plasma glucose (FPG)-lowering effect of KRP-104 in patients with type 2 diabetes inadequately controlled on metformin alone;
To compare effects of once daily (QD) dosing versus twice daily (BID) dosing of KRP-104 on HbA1c and FPG
To assess the effects of KRP-104 on post-prandial glucose dynamics and insulin sensitivity (homeostasis model index [HOMA-β]) in the setting of a Meal Tolerance Test(MTT)
Changes from pre-prandial to 2-hour post-prandial glucose, active GLP-1, insulin summarized by treatment group from Week 0 to Week 5 and Week 12. Percent change in 2-hour post-prandial glucose summarized by treatment group from Week 0 to Week 5 and Week 12.
To assess the safety and tolerability of KRP-104;
Full Information
NCT ID
NCT00525330
First Posted
September 3, 2007
Last Updated
August 14, 2013
Sponsor
ActivX Biosciences, Inc.
Collaborators
Kyorin Pharmaceutical Co.,Ltd
1. Study Identification
Unique Protocol Identification Number
NCT00525330
Brief Title
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of KRP-104 in Patients With Type 2 Diabetes Inadequately Controlled on Metformin Alone
Official Title
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of KRP-104 in Patients With Type 2 Diabetes Inadequately Controlled on Metformin Alone
Study Type
Interventional
2. Study Status
Record Verification Date
August 2013
Overall Recruitment Status
Completed
Study Start Date
September 2007 (undefined)
Primary Completion Date
August 2008 (Actual)
Study Completion Date
August 2008 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
ActivX Biosciences, Inc.
Collaborators
Kyorin Pharmaceutical Co.,Ltd
4. Oversight
5. Study Description
Brief Summary
To assess the safety and efficacy of chronic therapy with KRP-104, a novel DPP-IV inhibitor, in patients with Type 2 Diabetes on stable metformin therapy. In addition, an estimate of how much of the HbA1c response is attributable to nocturnal coverage will be explored.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
213 (Actual)
8. Arms, Groups, and Interventions
Arm Title
KRP-104 120 mg QD
Arm Type
Experimental
Arm Title
KRP-104 60 mg BID
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
KRP-104 QD Drug: Placebo Drug: Metformin
Intervention Description
KRP-104 120 mg: KRP-104 two 50 mg tablets and two 10 mg tablets 15 to 30 minutes before morning meal and 2 placebo tablets 15 to 30 minutes before evening meal
Intervention Type
Drug
Intervention Name(s)
Placebo Drug: Metformin
Intervention Description
Two tablets 15 to 30 minutes before each meal, morning and evening.
Intervention Type
Drug
Intervention Name(s)
KRP-104 BID Drug: Placebo Drug: Metformin
Intervention Description
KRP-104 60 mg: KRP-104 one 50 mg tablet plus one 10 mg tablet 15 to 30 minutes before each meal, morning and evening.
Primary Outcome Measure Information:
Title
The primary objective of this trial is to demonstrate the hemoglobin A1c (HbA1c)-lowering effects of KRP-104 in patients with type 2 diabetes inadequately controlled on metformin alone.
Time Frame
12-weeks
Secondary Outcome Measure Information:
Title
To assess the fasting plasma glucose (FPG)-lowering effect of KRP-104 in patients with type 2 diabetes inadequately controlled on metformin alone;
Time Frame
12-weeks
Title
To compare effects of once daily (QD) dosing versus twice daily (BID) dosing of KRP-104 on HbA1c and FPG
Time Frame
12 weeks
Title
To assess the effects of KRP-104 on post-prandial glucose dynamics and insulin sensitivity (homeostasis model index [HOMA-β]) in the setting of a Meal Tolerance Test(MTT)
Description
Changes from pre-prandial to 2-hour post-prandial glucose, active GLP-1, insulin summarized by treatment group from Week 0 to Week 5 and Week 12. Percent change in 2-hour post-prandial glucose summarized by treatment group from Week 0 to Week 5 and Week 12.
Time Frame
12 weeks
Title
To assess the safety and tolerability of KRP-104;
Time Frame
Daily for 12 weeks to 2 weeks post-treatment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age 18 to 70 years, inclusive;
Males and females of non-childbearing potential;
Diagnosis of type 2 diabetes mellitus according; and
On a stable dose of metformin monotherapy at randomization (can be on other oral therapies or naive at study entry
Exclusion Criteria:
History of type 1 diabetes mellitus or history of diabetic ketoacidosis or persistent hypoglycemia;
History or presence of alcoholism or drug abuse
Typical consumption of ≥10 drinks of alcohol weekly;
Presence of any of the following conditions:
Significant renal impairment (glomerular filtration rate <60 mL/min [to be calculated by the central laboratory]);
Diabetic retinopathy;
Diabetic gastroparesis;
Active liver disease (other than asymptomatic nonalcoholic fatty liver disease), cirrhosis, or symptomatic gallbladder disease;
Uncontrolled high blood pressure;
History or evidence of cardiovascular or pulmonary disease
Must meet other laboratory and Medical History clinical criteria. Please contact recruitment center for referrals
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David Orloff
Organizational Affiliation
Medpace, Inc.
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Tufail Syed
Organizational Affiliation
Medpace India
Official's Role
Study Chair
Facility Information:
City
San Diego
State/Province
California
Country
United States
12. IPD Sharing Statement
Learn more about this trial
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of KRP-104 in Patients With Type 2 Diabetes Inadequately Controlled on Metformin Alone
We'll reach out to this number within 24 hrs